课题基金 / 基金详情

项目摘要

项目成果

CHRISTINE M. EISCHEN的其他基金

相似基金

相关文献

中文摘要
翻译

英文摘要
 DESCRIPTION (provided by applicant): The Myc oncogene is overexpressed or dysregulated in at least 70% of all human malignancies, including B cell lymphomas. Myc is a transcription factor that drives cell cycle progression and induces cellular transformation that results in tumor development. Although significant advances have been made in recent years elucidating the genes that inhibit or contribute to Myc-induced tumor development, very little is known about the signaling pathways that are activated by Myc at any stage of tumor development. Moreover, the signaling pathways that are involved in cancers that become "addicted" or rely on Myc to continue to survive and grow remain unresolved. We have begun investigations into these open questions about Myc. We have recently determined that Myc activates the Ras signaling pathway in untransformed B cells, which inhibits Myc- induced apoptosis and significantly contributes to the transforming activity of Myc during B cell lymphomagenesis. However, it is unclear whether other signaling pathways are altered by Myc activity that contribute to the transformation ability of Myc, and if the Ras signaling pathway or other pathways are a factor in the oncogene addiction of the cancers that overexpress Myc. In addition, not all of the cells in a population may respond in the same way to Myc activation, resulting in population heterogeneity in response to Myc. Therefore, we hypothesize that in normal B cells, multiple signaling pathways are induced by Myc in the initial stages of transformation, and some of these contribute to lymphoma development and others to cell death. We also hypothesize that specific signaling pathways are required for Myc-addicted B cell lymphomas to grow and survive. To address these hypotheses we propose two Specific Aims. Aim 1 will focus on the signaling pathways altered by Myc in untransformed B cells. Aim 2 will focus on the pathways that mediate Myc addiction in B cell lymphomas. Recent advances in technology now allow analysis of signaling in single cells in a population, and dozens of individual signaling events on a per cel basis. Single cell analysis of signaling events will determine the pathways that are activated by Myc and the range of reactions to Myc in each Aim. Completion of these studies will significantly advance understanding into the initiating signaling events in Myc- induced B cell transformation and the pathways that contribute to Myc oncogene addiction. Our studies are also likely to result in the elucidation of novel therapeutically targetable pathways in B cell lymphoma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigating a new vulnerability in oral squamous cell carcinoma
  • 批准号:
    10714352
  • 项目类别:
  • 资助金额:
    $53.58万
  • 财政年份:
    2023
  • 负责人:
    CHRISTINE M. EISCHEN
  • 依托单位:
Design of the First Mdm2 Targeting PROTACs for treatment of p53 Mutant or Deficient Cancers
  • 批准号:
    10700091
  • 项目类别:
  • 资助金额:
    $52.91万
  • 财政年份:
    2022
  • 负责人:
    CHRISTINE M. EISCHEN
  • 依托单位:
BCLW in lymphoma survival and resistance to targeted BCL2 family therapies
  • 批准号:
    10532742
  • 项目类别:
  • 资助金额:
    $11.29万
  • 财政年份:
    2019
  • 负责人:
    CHRISTINE M. EISCHEN
  • 依托单位:
BCLW in lymphoma survival and resistance to targeted BCL2 family therapies
  • 批准号:
    10056214
  • 项目类别:
  • 资助金额:
    $42.98万
  • 财政年份:
    2019
  • 负责人:
    CHRISTINE M. EISCHEN
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: